SCHEMBL738448

SCHEMBL738448

Cc1ccc(-c2nnc(C)s2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.64
ALDH1A1 P00352 2/20 0.64
LMNA P02545 1/20 0.64
RAB9A P51151 8/20 0.50
NPC1 O15118 6/20 0.50
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HDAC1 Q13547 2/20 0.42
ALOX15 P16050 1/20 0.42
PTGS2 P35354 1/20 0.42
HDAC2 Q92769 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 1/20 0.42
TP53 P04637 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
NOTUM Q6P988 1/20 0.41
ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10000252 0.88 ALDH1A1 (0.72) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL31073516 0.83 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL26523431 0.83 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL9264165 0.83 KDM4E (0.60) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL14117651 0.83 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL17184682 0.83 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL17184845 0.83 CA1 (0.49) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL14970084 0.83 NPC1 (0.50) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL2421712 0.82 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL23329317 0.81 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1LMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240021012-A1 FINGERPRINT RECOGNITION SENSOR AND OPTICAL ELEMENT FUJIFILM CORPORATION (JP) 2024-01-18 US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 US disclosed
CN-111995620-B Preparation method of 1,3, 4-thiadiazole compound and compound prepared by same 重庆医科大学 2023-06-06 CN disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed
CN-111995620-A Preparation method of 1,3, 4-thiadiazole compound and compound prepared by same 重庆医科大学 2020-11-27 CN disclosed
US-20130200306-A1 SYNERGISTIC HOST-GUEST INTERACTIONS IN FLC MIXTURES FOR INCREASED POLARIZATION AND DECREASED SWITCHING SPEED MICRON TECHNOLOGY, INC. (US) 2013-08-08 US disclosed
US-20130172558-A1 NAPROXEN-BASED CHIRAL COMPOUNDS AND LIQUID CRYSTAL DISPLAY APPLICATIONS CITIZEN FINETECH MIYOTA CO., LTD. (JP) 2013-07-04 US disclosed
US-8420686-B2 Linked diimidazole antivirals ENANTA PHARMACEUTICALS, INC. (US) 2013-04-16 US disclosed
US-8388860-B2 Chiral compounds, liquid crystal compositions and polymer networks derived therefrom E I DU PONT DE NEMOURS AND COMPANY (US) 2013-03-05 US disclosed
US-20090161061-A1 Multilayer laminates comprising chiral nematic liquid crystals E. I. DU PONT DE NEMOURS AND COMPANY 2009-06-25 US disclosed
US-7534371-B2 Liquid crystalline compound, liquid crystalline composition and retardation film FUJIFILM CORPORATION (JP) 2009-05-19 US disclosed
US-7443900-B2 Laser gain medium for solid state dye lasers BASF AKTIENGESELLSCHAFT (DE) 2008-10-28 US disclosed
US-7443900-B2 Laser gain medium for solid state dye lasers BASF AKTIENGESELLSCHAFT (DE) 2008-10-28 US disclosed
US-20080186443-A1 Liquid Crystal Composition, Retardation Plate, and Elliptic Polarizing Plate FUJIFILM CORPORATION (JP) 2008-08-07 US disclosed
US-20080169448-A1 Liquid crystalline compound, liquid crystalline composition and retardation film FUJIFILM CORPORATION (JP) 2008-07-17 US disclosed
US-7364670-B2 Liquid crystalline compound, liquid crystalline composition and retardation film FUJIFILM CORPORATION (JP) 2008-04-29 US disclosed
EP-1092721-B1 Chiral glucosides and their use as chiral dopants for the production of cholesteric liquid crystalline compositions BASF AG (DE) 2007-12-19 EP disclosed
US-7258902-B2 Chiral 3,4-dihydro-2H-pyran compounds BASF AKTIENGESELLSCHAFT (DE) 2007-08-21 US disclosed
US-7258902-B2 Chiral 3,4-dihydro-2H-pyran compounds BASF AKTIENGESELLSCHAFT (DE) 2007-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080169448-A1 Liquid crystalline compound, liquid crystalline composition and retardation film NCAPD2, RCC1, CCND2 SMN1; SMN2 4507/4885ALDH1A1 4792/4885LMNA 496/4885
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 SMN1; SMN2 3/4885ALDH1A1 308/4885LMNA 340/4885
US-20130172558-A1 NAPROXEN-BASED CHIRAL COMPOUNDS AND LIQUID CRYSTAL DISPLAY APPLICATIONS CRY1, CRY2, ALOX5 SMN1; SMN2 3451/4885ALDH1A1 1781/4885LMNA 2839/4885
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO SMN1; SMN2 4237/4885ALDH1A1 184/4885LMNA 4767/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO SMN1; SMN2 4237/4885ALDH1A1 184/4885LMNA 4767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.